ADVERTISEMENT

Dual incretin agent tirzepatide produces significant weight loss in people with obesity

Miriam Tucker   |   Clinical Summary   |   10 June 2022
ADVERTISEMENT

Takeaway

  • The once-weekly injectable tirzepatide produced significant weight loss in adults with obesity.

Why this matters

  • Obesity increases risks for morbidity and mortality.
  • Tirzepatide, a dual long-acting glucagon-like peptide-1 receptor agonist and glucose-dependent insulinotropic polypeptide, was approved in the United States and is under European regulatory review for treating type 2...

          

January Challenge

Ends in 2d 16h
left
right

Topic Challenges

left
right